Study of AZD0754 in Participants With Metastatic Prostate Cancer

Active:	Yes
Cancer Type:	Prostate Cancer Unknown Primary	NCT ID:	NCT06267729
Trial Phases:	Phase I Phase II	Protocol IDs:	D9660C00001 (primary) NCI-2024-01754
Eligibility:	18 - 130 Years, Male	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06267729

Summary

The purpose of this study is to evaluate the safety, tolerability, and antitumour
activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

Objectives

This is a first-time in human, multi-center, open label, Phase I/II study of AZD0754
autologous CAR T-cell therapy administered intravenously to participants with metastatic
prostate cancer. The study is intended to assess the safety, cellular kinetics,
pharmacodynamics, preliminary efficacy, and feasibility of manufacturing AZD0754 for
patients with metastatic prostate cancer.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.